Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
DUBLIN--(BUSINESS WIRE)--Horizon announced that clinical data for teprotumumab in the treatment of active thyroid eye disease will be presented at the ACR Annual Meeting.